Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

BMC Psychiatry

Josep Maria Haro³  Martin Dossenbach⁴  Jamie Karagianis¹  Roberto Brugnoli⁵  Diego Novick²  Jihyung Hong² 

[1] Eli Lilly Canada Inc, Toronto, Ontario, Canada;European Health Outcomes Research, Eli Lilly and Company, Windlesham, Surrey, UK;Parc Sanitari Sant Joan de Deu, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain;Eli Lilly Ges.m.b.H, Wien, Austria;Fondazione Italiana per lo studio della Schizophrenia, Rome, Italy

关键词: Risperidone;    Olanzapine;    Switching;    Schizophrenia;    Antipsychotic;   

Others  :  1124214
DOI  :  10.1186/1471-244X-12-218

 received in 2011-11-04, accepted in 2012-11-28,  发布年份 2012

【 摘 要 】

Background

With many atypical antipsychotics now available in the market, it has become a common clinical practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting.

Methods

W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from 37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking olanzapine at baseline and subsequently made the first switch to risperidone (n=162) and vice versa (n=136). Clinical status was assessed at the visit when the first switch was made (i.e. before switching) and after switching. Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear regression models assessed the association between medication switch and change in the Clinical Global Impression-Schizophrenia (CGI-SCH) overall score or change in weight. In addition, Kaplan-Meier survival curves and Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse (symptom worsening as assessed by the CGI-SCH scale or hospitalization).

Results

48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication without further switches (p=0.019). Patients switching to olanzapine were significantly less likely to experience relapse (hazard ratio: 3.43, 95% CI: 1.43, 8.26), extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89) and amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13). No significant difference in weight change was, however, found between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a significantly greater change in those who switched to olanzapine (difference of 0.29 points, p=0.013).

Conclusion

Our study showed that patients who switched from risperidone to olanzapine were likely to experience a more favorable treatment course than those who switched from olanzapine to risperidone. Given the nature of observational study design and small sample size, additional studies are warranted.

【 授权许可】

   
2012 Hong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A: Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs 2004, 18:157-164.
• [2]Ashcroft DM, Frischer M, Lockett J, Chapman SR: Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf 2002, 11:285-289.
• [3]Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M: Prescription of antipsychotic drugs by office-based physicians in the United States, 1989–1997. Psychiatr Serv 2002, 53:425-430.
• [4]Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H: Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry 2006, 67:1577-1582.
• [5]Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH: Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001, 62(Suppl 2):28-34.
• [6]Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ: Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin 2008, 24:1399-1405.
• [7]Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M: The european schizophrenia outpatient health outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003, 107:222-232.
• [8]Haro JM, Edgell ET, Novick D, et al.: Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005, 111:220-231.
• [9]Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S: Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005, 66:1021-1030.
• [10]Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ: Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009, 63:1578-1588.
• [11]APA: Diagnostic and statistical manual of mental disorders. Fourth edition. Washington, DC: American Psychiatric Association (APA); 1994.
• [12]WHO: The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organisation (WHO); 1992.
• [13]Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, et al.: The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003, 416:16-23.
• [14]Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M: Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2006, 26:571-578.
• [15]Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ: Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 2008, 6:17. BioMed Central Full Text
• [16]Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, et al.: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622.
• [17]Jayaram MB, Hosalli P, Stroup TS: Risperidone versus olanzapine for schizophrenia. Cochrane database of systematic reviews cochrane database of systematic reviews. 2006. Issue 2:Art. No.: CD005237
• [18]Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17:407-418.
• [19]Namjoshi M, Young C, Huang L, et al.: Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol 2002, 12:S315.
• [20]Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB: Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005, 187:137-142.
• [21]Knapp M: Costs of schizophrenia. Br J Psychiatry 1997, 171:509-518.
• [22]Lindstrom E, Bingefors K: Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000, 18:106-124.
• [23]Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999, 35:51-68.
• [24]Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs 1999, 8:443-452.
• [25]Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56.
• [26]Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D: Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007, 17:235-244.
• [27]Bobes J, Garc APMP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A: Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003, 29:125-147.
• [28]Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, Naber D: Olanzapine vs. Other antipsychotics in actual out-patient settings: six months tolerability results from the European schizophrenia Out-patient health outcomes study. Acta Psychiatr Scand 2005, 111:232-243.
• [29]Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, Hummer M, Fleischhacker WW: Switching between second-generation antipsychotics: why and how? CNS Drugs 2005, 19:27-42.
• [30]Highlights of prescribing information for zyprexa. http://www.zyprexa.com/Hcp/Pages/physiciansandhealthcareprofessionalshome.aspx webcite
• [31]Weiden PJ, Buckley PF: Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry 2007, 68(Suppl 6):14-23.
• [32]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
• [33]Takahashi H, Yoshida K, Ishigooka J, Higuchi H: Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1067-1072.
• [34]van Bruggen M, van Amelsvoort T, Wouters L, Dingemans P, de Haan L, Linszen D: Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology 2009, 34:989-995.
• [35]Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F: Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy 2006, 5:11-25.